Astrolabe Diagnostics

Executive Summary

Astrolabe Diagnostics offers a cloud-based cytometry platform that enables researchers to analyze single-cell data rapidly, moving from raw samples to biological insights in hours. The platform emphasizes bioinformatics and scalability, targeting the growing single-cell analysis market. Founded in 2018 and headquartered in San Diego, the company is privately held with no disclosed funding or revenue. Its technology addresses the need for efficient data analysis in immunology, oncology, and drug development. While the company has not announced major partnerships or products, its platform could gain traction as the field adopts cloud-based solutions. With no disclosed financials or clear commercial milestones, the company appears to be in an early stage, requiring further validation.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major pharma company for platform adoption40% success
• Q4 2026Release of next-generation analytics module with AI capabilities50% success
• Q3 2026Series A funding announcement35% success